2021 Volume 58 Issue 3 Pages 301-305
A nine-month-old female infant with a left adrenal gland tumor was referred to our hospital. She was diagnosed as having an intermediate-risk neuroblastoma as per the Children’s Oncology Group risk classification. After five courses of multidrug chemotherapy, the primary tumor was excised and the metastatic liver tumors were biopsied. Although residual histopathological neuroblastoma cells were confirmed in both the primary tumors and liver metastases, treatment was terminated after one additional course of chemotherapy. After the treatment, magnetic resonance imaging and metaiodobenzylguanidine scintigraphy findings revealed liver metastases. The treatment ended two years and one month ago, but no recurrence has been detected since then. In the case of a neuroblastoma with favorable biological factors, it may be advisable to forgo additional treatment for residual tumor after induction therapy even when histopathological neuroblastoma cells remain.
